Frontiers in Oncology,
Год журнала:
2023,
Номер
13
Опубликована: Окт. 24, 2023
Lung
cancer
is
a
malignancy
with
high
incidence
and
mortality
rates
globally,
it
has
5-year
survival
rate
of
only
10%–20%.
The
significant
heterogeneity
in
clinical
presentation,
histological
features,
multi-omics
findings,
drug
sensitivity
among
different
lung
patients
necessitate
the
development
personalized
treatment
strategies.
current
precision
medicine
for
cancer,
primarily
based
on
pathological
genomic
testing,
fails
to
meet
needs
clinically
refractory
cancer.
organoids
(LCOs)
are
derived
from
tumor
cells
within
tissues
generated
through
three-dimensional
tissue
culture,
enabling
them
faithfully
recapitulate
vivo
characteristics
heterogeneity.
establishment
series
LCOs
biobanks
offers
promising
platforms
efficient
screening
identification
novel
targets
anti-tumor
discovery.
Moreover,
provide
supplementary
decision-making
factors
enhance
thereby
addressing
limitations
associated
pathology-guided
approaches
managing
This
article
presents
comprehensive
review
construction
methods
potential
applications
both
preclinical
research.
It
highlights
significance
biomarker
exploration,
resistance
investigation,
target
identification,
screening,
as
well
microfluidic
technology-based
high-throughput
Additionally,
discusses
future
prospects
this
field.
Nature Communications,
Год журнала:
2025,
Номер
16(1)
Опубликована: Май 11, 2025
Although
EGFR
tyrosine
kinase
inhibitors
(EGFR-TKIs)
are
effective
for
EGFR-mutant
lung
adenocarcinoma
(LUAD),
resistance
inevitably
develops
through
diverse
mechanisms,
including
secondary
genetic
mutations,
amplifications
and
as-yet
undefined
processes.
To
comprehensively
unravel
the
mechanisms
of
EGFR-TKI
resistance,
we
establish
a
biobank
patient-derived
cancer
organoids,
encompassing
cases
previously
treated
with
EGFR-TKIs.
Through
comprehensive
molecular
profiling
single-cell
analysis,
here
identify
subgroup
EGFR-TKI-resistant
LUAD
organoids
that
lacks
known
resistance-related
lesions
instead
exhibits
basal-shift
phenotype
characterized
by
hybrid
expression
LUAD-
squamous
cell
carcinoma-related
genes.
Prospective
gene
engineering
demonstrates
NKX2-1
knockout
induces
transformation
along
EGFR-target
therapy
resistance.
Basal-shift
LUADs
frequently
harbor
CDKN2A/B
loss
sensitive
to
CDK4/6
inhibitors.
Our
organoid
library
not
only
offers
valuable
resource
research
but
also
provides
insights
into
underpinnings
facilitating
development
therapeutic
strategies.
Frontiers in Oncology,
Год журнала:
2023,
Номер
13
Опубликована: Окт. 24, 2023
Lung
cancer
is
a
malignancy
with
high
incidence
and
mortality
rates
globally,
it
has
5-year
survival
rate
of
only
10%–20%.
The
significant
heterogeneity
in
clinical
presentation,
histological
features,
multi-omics
findings,
drug
sensitivity
among
different
lung
patients
necessitate
the
development
personalized
treatment
strategies.
current
precision
medicine
for
cancer,
primarily
based
on
pathological
genomic
testing,
fails
to
meet
needs
clinically
refractory
cancer.
organoids
(LCOs)
are
derived
from
tumor
cells
within
tissues
generated
through
three-dimensional
tissue
culture,
enabling
them
faithfully
recapitulate
vivo
characteristics
heterogeneity.
establishment
series
LCOs
biobanks
offers
promising
platforms
efficient
screening
identification
novel
targets
anti-tumor
discovery.
Moreover,
provide
supplementary
decision-making
factors
enhance
thereby
addressing
limitations
associated
pathology-guided
approaches
managing
This
article
presents
comprehensive
review
construction
methods
potential
applications
both
preclinical
research.
It
highlights
significance
biomarker
exploration,
resistance
investigation,
target
identification,
screening,
as
well
microfluidic
technology-based
high-throughput
Additionally,
discusses
future
prospects
this
field.
